Maven Clinic review

Add the care membership to the pharmacy charge

Maven’s direct GLP-1 program lists a $39 first-month membership, then $150 monthly, with medication billed separately by the pharmacy. Its lower self-pay medication options start around $149, giving a combined $188 first month and $299 ongoing when that product and price apply. The membership alone is not the total cost of medication treatment.

The starting Zepbound amount is $299 for the medication, giving $338 initially and $449 ongoing when paired with the corresponding membership payment. The amount changes with the selected product and dose. Ask for a complete prescription-specific quote rather than applying the cheapest medication floor to every Wegovy, Zepbound or other brand option in the table.

Refill timing can change higher-dose medication prices

Maven’s self-pay table distinguishes several formulations and dose levels. Some higher-dose quotes depend on refilling within a forty-five-day window, with medication amounts otherwise rising to figures such as $499 or $699. Those are pharmacy costs before adding the care membership, not complete recurring treatment totals.

Clarify which conditions apply to the actual prescription and what happens if a refill is delayed or treatment pauses. A missed discount condition is a financial issue to understand, not a reason to change clinical instructions or obtain medication unnecessarily. The clinician and pharmacy should explain the intended refill schedule while the payment terms identify the amount due under the applicable offer.

This program offers approved brands, not compounded products

Maven says it prescribes FDA-approved GLP-1 products and does not offer compounded formulations. Its menu includes different semaglutide products, Zepbound and other named options. Those choices have product-specific labeling and instructions; they should not be treated as interchangeable because they share a broad weight-management category or appear on one pricing page.

Ask which product is proposed, how it is supplied and which pharmacy bills for it. The membership covers clinical access and related services, while the actual medication charge remains separate. That arrangement may appeal to someone who wants a branded route, but it should be compared with another brand-prescribing service using the full care-plus-medication cost available to the patient.

The broader clinical scope is relevant, with limits

Maven’s eligibility description specifically considers PCOS, perimenopause, reproductive planning and recent pregnancy, rather than relying only on a general women-focused slogan. Its wider virtual clinic includes OB-GYN and reproductive-health specialties, and the program describes nutrition and strength-coaching support. Those are identifiable service features to ask about.

They do not establish that any particular medication is appropriate after pregnancy or during breastfeeding, or that every specialty appointment is included in the purchased program. Confirm the actual clinician, relevant scope of care and which coaching consultations are covered. If Maven is already available through an employer or health plan, establish whether that benefit covers the direct GLP-1 service before paying separately.

The membership has a defined stopping timetable

The published terms require changes at least forty-eight hours before the next billing date. Access continues through the paid period without a prorated refund, while a separate full-refund provision covers the first three business days after signup if no services have been received. Read the applicable conditions before relying on either provision.

Maven does not publish a complete state list for this service; prescribing and services vary by location. It may interest someone seeking a branded-medication route within a broader reproductive-health platform. The financial decision needs the actual membership, pharmacy charge and refill conditions together, while the care decision needs a named professional and clear eligibility assessment rather than an assumption that broad specialty access guarantees a particular prescription.